I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 335370631 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Signature:

(Georgina Matos)



PATENT Docket No. 252312005704

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Stephen M. COUTTS et al.

Serial No.: 09/752,533

Filing Date: December 29, 2000

For: CONJUGATES OF CHEMICALLY

DEFINED NON-POLYMERIC

VALENCY PLATFORM MOLECULES

AND BIOLOGICALLY ACTIVE

MOLECULES

Examiner: D. Lukton

Group Art Unit: 1653

SUPPLEMENTAL INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

12/14/2004 RMEBRAHT 00000003 031952 09752533

02 FC:1806

180.00 DA

	With the application; accordingly, no fee or separate requirements are required.					
	Before the mailing of a first Office Action after the filing of a Request for Continued					
	Exami	nation under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97				
	(e)(1) has been provided.					
	Within three months of the application filing date or before mailing of a first Office Action					
	on the merits; accordingly, no fee or separate requirements are required. However, if					
	applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.					
\boxtimes	After receipt of a first Office Action on the merits but before mailing of a final Office Action					
	or Notice of Allowance.					
		A fee is required. A check in the amount of is enclosed.				
	\boxtimes	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to				
		this submission in duplicate.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is				
		believed to be due.				
	After r	nailing of a final Office Action or Notice of Allowance, but before payment of the				
	issue fee.					
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the				
		amount of is enclosed.				
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal				
		form (PTO/SB/17 is attached to this submission in duplicate.)				

This Supplemental Information Disclosure Statement is submitted:

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

Application Serial No. 09/752,533

PATENT Docket No. 252312005704

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 2523123005704. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 3, 2004

Respectfully submitted,

Charles D. Holland

Registration No. 35,196

foi

Shannon Thomas Reaney

Registration No.: 52,285

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304

(650) 813-5744

DEC 0 3 2004 TRADE Septitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

2 Sheet 1 of

Complete if Known				
Application Number	09/752,533			
Filing Date	December 29, 2000			
First Named Inventor	Stephen M. COUTTS			
Art Unit	1653			
Examiner Name	D. Lukton			
Attorney Docket Number	252312005704			

	U.S. PATENT DOCUMENTS							
Examiner	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant			
Initials*		Number-Kind Code ² (if known)			Figures Appear			
	1.	US-4,234,563	11-18-1980	Rippe				
	2.	US-4,399,121	08-16-1983	Albarella et al.				
	3.	US-4,558,120	12-10-1985	Tomalia et al.				
	4.	US-4,568,737	02-04-1986	Tomalia et al.				
	5.	US-4,822,594	04-18-1989	Gibby				
	6.	US-5,135,737	08-04-1992	Keana				
	7.	US-5,219,564	06-15-1993	Zalipsky et al.				
	8.	US-5,229,366	07-20-1993	Tsukada et al.				
	9.	US-5,229,490	07-20-1993	Tam				
	10.	US-5,338,532	08-16-1994	Tomalia et al.				
	11.	US-6,011,020	01-04-2000	Gold et al.				

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages		
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		Applicant of Cited Document	or Relevant Figures Appear	T⁰	
	12.	DD 287 950-A5	03-14-1991	Zent Molekular AG		1	
	13.	EP 0 457 438-A2	11-21-1991	Celltech Ltd			
	14.	WO 88/01178-A1	02-25-1988	The Dow chemical Company			
	15.	WO 90/10448-A2	09-20-1990	Genentech Inc.			

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	16.	Aharoni, S.M. et al. (1982). "Size and Solution Properties of Globular tert-Butyloxycarbonyl-poly(a,e-L-lysine)," <i>Macromolecules</i> 15(4):1093-1098.	
	17.	Hudecz, F. et al. (1992). "Synthesis, Conformation, Biodistribution, and in Vitro Cytotoxicity of Daunomycin-Branched Polypeptide Conjugates," <i>Bioconjugate Chem.</i> 3(1):49-57.	
	18.	Hudecz, F. et al. (1993). "Influence of Carrier on Biodistribution and in Vitro Cytotoxicity of Methotrexate-Branched Polypeptide Conjugates," <i>Bioconjugate Chem.</i> 4(1):25-33.	
	19.	McLean, G.W. et al. (1992). "Rapid Attachment of a Helper T Cell Epitope to Branched Peptides by Fragment Condensation to Give Enhanced Immunogenicity," <i>Journal of Immunological Methods</i> 155:113-120.	
	20.	Peacock, J.S. et al. (1979). "Antigenic Stimulation of Lymphocytes. II. Immunogenicity of Dinitrophenyl-Polyethylene Oxide Antigens," <i>Cellular Immunology</i> 43:382-387.	
	21.	Tam, J.P. (August 1988). "Synthetic Peptide Vaccine Design: Synthesis and Properties of a High-Density Multiple Antigenic Peptide System," <i>Proc. Natl. Acad. Sci. USA</i> 85:5409-5413.	

		_		 	_
Examiner	Date		-		ĺ
Signature	Considered	<u> </u>		 	
0001				 	_

DEC 0 3 2004 3

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known					
Application Number	09/752,533				
Filing Date	December 29, 2000				
First Named Inventor	Stephen M. COUTTS				
Art Unit	1653				
Examiner Name	D. Lukton				
Attorney Docket Number	252312005704				

22.	Tomalia, D.A. et al. (1985). "A New Class of Polymers: Starburst-Dendritic Macromolecules,"	
	Polymer Journal 17(1):117-132.	

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Date Signature Considered

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.